Abstract Information

The deadline to submit research for a regular abstract, Young Investigator Award abstract and/or late-breaking abstract application is 5 p.m. PDT on July 29, 2021. For more information, see the 2021 Regular and Late-Breaking Abstract Reference Guide or continue scrolling to learn more about specific abstract categories and timelines.

    Regular and Young Investigator Award Abstracts


    Late-Breaking Abstracts

    Submit Now

    The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations Abstracts

    Submit Now

    New Opportunity
    Submit an Abstract to The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations

    Submit Now


    *The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations Abstracts will not be published in the Journal for ImmunoTherapy of Cancer (JITC) and are subject to a different timeline and review process than the 36th Annual Meeting Abstracts.


    Abstract Categories and Timelines

    Important Abstract Dates

    Regular and Late-Breaking

    Date Details

    April 23, 2021

    Regular abstracts, Young Investigator Award abstracts, Late-Breaking abstracts application submission site opens

     June 30, 2021

    Abstract site opens for the Evolution of Immunotherapy: An Exploration of Immunity, Beyond T cells, CAR T in Solid Tumors and Novel Combinations

    July 29, 2021

    Regular abstracts, Young Investigator Award abstracts, Late-Breaking abstracts application site closes at 5 p.m. PDT

    Aug. 10, 2021

    Late-Breaking Abstracts Application notifications sent

    Aug. 19, 2021

    Abstract site closes for the Evolution of Immunotherapy: An Exploration of Immunity, Beyond T cells, CAR T in Solid Tumors and Novel Combinations

    Aug. 19, 2021

    Late-Breaking abstract submission site opens

    Aug. 27, 2021

    Regular abstract and Young Investigator Award abstract notifications sent

    Aug. 31, 2021

    Late-Breaking abstract submission site closes at 5 p.m. PDT

    Sept. 2, 2021

    Regular abstract presentation acceptance confirmations
    Deadline for Regular abstract withdrawals (withdrawals must be made by emailing education@sitcancer.org to indicate withdrawal)

    Sept. 20, 2021

    Late-Breaking abstract notifications sent

    Sept 24, 2021

    Late-Breaking abstract presentation acceptance confirmation due
    Deadline for Late-Breaking abstract withdrawals

    Oct. 1, 2021

    Regular abstract title and author information released at 8 a.m. EST

    Nov. 1 2021

    Late-Breaking abstract title and author information released at 8 a.m. EST

    Nov. 9, 2021

    Embargo lifted and full Regular and Late-Breaking abstracts made public at 8 a.m. EST
    All abstracts are available in the Journal for ImmunoTherapy of Cancer (JITC) supplement

    Nov. 10-14, 2021

    36th Annual Meeting & Pre-Conference Programs

    Dec. 2021

    Final supplement published in JITC

    Poster Presentation Dates

    SITC is monitoring the COVID-19 situation and plans to announce any decisions in mid-summer. More information about requirements for accepted abstract presentations is forthcoming.

    All odd-numbered posters will be presented on Friday, Nov. 12, 2021, while even-numbered posters will be presented on Saturday, Nov. 13, 2021.

    Posters will be on display from 7 a.m.–8 p.m., with the presenting authors required to be at their posters during lunch (12:40–2:10 p.m. on Friday, Nov. 12, and 12:30–2 p.m. on Saturday, Nov. 13) and also during the poster reception (7–8:30 p.m. on Friday, Nov. 12, and 7–8:30 p.m. on Friday, Nov. 12).

    Regular Abstracts

    The time frame to submit your latest research in the cancer immunotherapy field to the 36th Annual Meeting & Pre-Conference Programs (SITC 2021) for consideration as an oral abstract presentation, rapid oral abstract presentation, and/or poster abstract presentation is April 23, 2021, until 5 p.m. PDT on July 29, 2021.

    Late-Breaking Abstracts

    Late-Breaking abstract (LBA) submission is solely for abstracts with late-breaking data and not for abstracts submitted “late”. The late-breaking abstract deadline is not intended to be an extension of the general submission deadline.

    All LBA application submissions are due by 5 p.m. PDT on July 29, 2021, to be eligible for the LBA submission period. Applications will be reviewed and all submitters will be notified if they qualify to submit a late-breaking abstract during the submission period from Aug. 19, 2021, to 5 p.m. PDT on Aug. 31, 2021. If an application does not qualify for late-breaking abstract submission, the submitter will be notified by Aug. 10, 2021, and will have the opportunity to submit a regular abstract by 5 p.m. PDT on Aug. 13, 2021.

    LBAs are considered for, but not limited to, oral abstract presentations during the LBA Sessions from 12:10–12:40 p.m. on Friday, Nov. 12, 2021, and 12–12:30 p.m. on Saturday, Nov. 13, 2021.

    Young Investigator Award Abstracts

    Regular abstracts with primary and presenting authors that are students, postdoctoral research fellows, clinical fellows, or junior faculty with three or fewer years on staff and are current SITC members, may be eligible to receive a Young Investigator Award. Young Investigator Award abstracts require a letter of recommendation as well as additional information regarding the percentage of contribution by the primary and presenting author.

    Those selected for the Presidential Travel Award will be invited to give an oral abstract presentation during the Presidential Session from 2–3:25 p.m. on Saturday, Nov. 13, 2021.

    For more information about the Young Investigator Awards, please click here.

    Reasons to Submit an Abstract to SITC 2021

    • Free submission for members and nonmembers (view important submission dates)

    • Young Investigator Awards are offered in conjunction with regular abstract submission

    • All accepted abstracts will be published as a supplement in the Journal for ImmunoTherapy of Cancer (JITC), the society’s global, open access, peer-reviewed journal

    • Multiple oral presentation opportunities available

    • The opportunity to present and discuss your research with luminaries in the immunotherapy field

    49093590382_26dd6f3415_b.jpg
    49093590382_26dd6f3415_b.jpg